UK Markets close in 5 hrs

ABIVAX Société Anonyme (AAVXF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
32.000.00 (0.00%)
At close: 08:30AM EST
Full screen
Trade prices are not sourced from all markets
Previous close32.00
Open32.00
Bid0.00 x 0
Ask0.00 x 0
Day's range32.00 - 32.00
52-week range21.14 - 39.85
Volume38
Avg. volume6
Market cap535.398M
Beta (5Y monthly)1.18
PE ratio (TTM)N/A
EPS (TTM)-2.62
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • EQS Group

    Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis

    DGAP-News: ABIVAX / Key word(s): Study13.01.2022 / 08:00 The issuer is solely responsible for the content of this announcement.Abivax receives EMA Scientific Advice supportive of moving ABX464 into phase 3 clinical testing in ulcerative colitis The responses from the European Medicines Agency (EMA) within the scientific advice meeting support moving 25mg and 50mg ABX464 into a phase 3 clinical program in ulcerative colitis (UC) Abivax to present at the virtual J.P. Morgan Healthcare Conference o

  • EQS Group

    Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference

    DGAP-News: ABIVAX / Key word(s): Conference15.12.2021 / 18:30 The issuer is solely responsible for the content of this announcement.Abivax to present at the J.P. Morgan 40th Annual Healthcare Conference Abivax's presentation at the virtual J.P. Morgan Healthcare Conference scheduled for Thursday, January 13, 2022, at 12:00-12:40 pm ET (9:00-9:40 am PST and 6:00-6:40 pm CET) FDA end-of-phase-2 feedback received, raising no objections to proceeding ABX464 into pivotal phase 3 testing in ulcerative

  • EQS Group

    Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitis

    DGAP-News: ABIVAX / Key word(s): Study01.12.2021 / 19:30 The issuer is solely responsible for the content of this announcement.Abivax receives FDA feedback with guidance on advancing ABX464 into phase 3 clinical testing in ulcerative colitisEnd-of-phase-2 response from the US regulatory agency (FDA) provides guidance and a path forward to advance ABX464 into a phase 3 clinical program in ulcerative colitis (UC)PARIS, France, December 1, 2021 - 7:30 pm (CET) - Abivax SA (Euronext Paris: FR0012333